Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review

por Dempke, Wolfram C. M., Fenchel, Klaus
Publicado 2021

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?

por Dempke, Wolfram C. M., Fenchel, Klaus, Reuther, Susanne, Murphy, Michael F.
Publicado 2022

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis

por Manz, Kirsi M., Fenchel, Klaus, Eilers, Andreas, Morgan, Jonathan, Wittling, Kirsten, Dempke, Wolfram C. M.
Publicado 2019

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

por Frost, Nikolaj, Christopoulos, Petros, Kauffmann-Guerrero, Diego, Stratmann, Jan, Riedel, Richard, Schaefer, Monica, Alt, Jürgen, Gütz, Sylvia, Christoph, Daniel C., Laack, Eckart, Faehling, Martin, Fischer, Richard, Fenchel, Klaus, Haen, Sebastian, Heukamp, Lukas, Schulz, Christian, Griesinger, Frank
Publicado 2021

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

por Wang, Song-Yau, Holzhey, Tanja, Heyn, Simone, Zehrfeld, Thomas, Fricke, Susann, Hoffmann, Franz Albert, Becker, Cornelia, Braunert, Leanthe, Edelmann, Thomas, Paulenz, Inessa, Hitzschke, Marcus, Flade, Franziska, Schwarzer, Andreas, Fenchel, Klaus, Franke, Georg-Nikolaus, Vucinic, Vladan, Jentzsch, Madlen, Schwind, Sebastian, Hell, Saskia, Backhaus, Donata, Lange, Thoralf, Niederwieser, Dietger, Scholz, Markus, Platzbecker, Uwe, Pönisch, Wolfram
Publicado 2022